Repligen (RGEN) Research & Development (2010 - 2026)

Repligen (RGEN) has 17 years of Research & Development data on file, last reported at $14.5 million in Q1 2026.

• On a quarterly basis, Research & Development rose 19.35% year-over-year to $14.5 million in Q1 2026; TTM through Mar 2026 was $55.7 million, a 26.4% increase from a year earlier, with the FY2025 full-year figure at $54.2 million, up 25.41% from the prior year.
• Research & Development for Q1 2026 stood at $14.5 million, up from $13.1 million in the prior quarter.
• Over the last five years, Research & Development for RGEN reached as high as $14.5 million in Q1 2026 and fell as low as $9.7 million in Q2 2023.
• Historically, Research & Development has averaged $11.6 million across 5 years, with a median of $11.2 million in 2024.
• Across the five-year window, Research & Development surged 59.68% in 2022 and dropped 8.2% in 2024, its largest moves.
• Year by year, Research & Development stood at $11.1 million in 2022, then retreated by 7.45% to $10.3 million in 2023, then grew by 13.53% to $11.7 million in 2024, then advanced by 12.36% to $13.1 million in 2025, then increased by 10.2% to $14.5 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $14.5 million in Q1 2026, $13.1 million in Q4 2025, and $14.2 million in Q3 2025.